Chime Biologics, a Wuhan, China-based contract development and manufacturing company, secured a total commitment of US$190m investment from institutional investors, with over $100m already closed, in Series A+ financing.
The round was led by VMS Group, followed by Fidelity International and Panacea Venture. Previously, Chime Biologics had just completed its Series A round financing of US$125m in early 2020.
Chime Biologics has built a GE KuBio modular bio-manufacturing facility in Wuhan Bio-Lake Biotech Industry Development Zone of China (China Optics Valley). The facility complies with global quality standards of ICH, FDA, EMA and NMPA. With its facility and rich experience in bio-manufacturing, Chime Biologics provides one-stop integrated solutions to support the needs of the bio-pharmaceutical industry from early drug development to late stage clinical and commercial cGMP production.
In order to meet the demands for CDMO services from various customers, Chime Biologics has already started the second phase of its facility expansion to increase the total manufacturing capacity to more than 140,000L within the next 5 years.
Led by Mr. James Huang, Executive Chairman, and Dr. John (Xianfang) Zeng, CEO, Chime Biologics is a CDMO with operations in China that provides outsourcing services for biopharmaceutical development and manufacturing. Its world’s first GE KuBio facility is located at Wuhan’s Bio-Lake biotech industry development zone of China, with clear path to expand the total capacity up to 140,000+ liters in the near future. Chime Biologics is ISO 14001:2015 and ISO 45001:2018 certified. Since 2016, the company has been providing customers with clinical materials for pre-clinical and clinical stages globally and supporting their production at various scales from 50L, 200L, 500L to 2,000L across IND-enabling studies to late-stage process development, scale-up, process characterization and process performance qualification. Since then, Chime Biologics has been providing clinical supply to over 20 countries worldwide.
FinSMEs
26/03/2021